WILMINGTON, Mass.--(BUSINESS WIRE)--CardioTech International, Inc. (AMEX: CTE), a developer and manufacturer of advanced medical devices and materials for the treatment of a broad range of disease states, today announced that it has received all necessary approvals to add a second medical center for the clinical trial of CardioPass™ , the Company’s proprietary synthetic coronary bypass graft.
